May 2024 Letter to Shareholders
VANCOUVER, Washington, May 16, 2024 (GLOBE NEWSWIRE) —
Dear Shareholders,
I write today to provide an update on CytoDyn Inc. (“CytoDyn” or “Company”), as we approach the end of our 2024 fiscal year (May 31, 2024), and to sincerely thank you for your unwavering support.
Related news for (CYDY)
- CytoDyn Releases ESMO Breast Cancer Meeting Poster
- CytoDyn Announces Data Suggesting Novel Mechanism of Action of Leronlimab for the Treatment of Solid Tumors
- CytoDyn Appoints Biotech Veteran Robert E. Hoffman as Chief Financial Officer
- CytoDyn Leadership Team To Attend ESMO Breast Cancer Meeting in Munich, Germany
- CytoDyn Announces Promising Survival Observations in mTNBC Patients Treated with Leronlimab